175 related articles for article (PubMed ID: 38084732)
1. Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer.
Yuan J; Li X; Wang F; Liu H; Guan W; Xu G
Exp Biol Med (Maywood); 2023 Dec; 248(23):2198-2209. PubMed ID: 38084732
[TBL] [Abstract][Full Text] [Related]
2. IGF2BP2 maybe a novel prognostic biomarker in oral squamous cell carcinoma.
Wang X; Xu H; Zhou Z; Guo S; Chen R
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35129592
[TBL] [Abstract][Full Text] [Related]
3. Prognostic marker C3AR1 is associated with ovarian cancer cell proliferation and immunosuppression in the tumor microenvironment.
Huang J; Zhou L; Deng K
J Ovarian Res; 2023 Apr; 16(1):64. PubMed ID: 37005667
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
Xu F; Liu T; Zhou Z; Zou C; Xu S
Front Immunol; 2021; 12():749369. PubMed ID: 34745121
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of cuproptosis-associated genes for predicting immunotherapy response in single-cell and multi-cohort studies.
Li H; Wang Y; Li G; Xiong J; Qin L; Wen Q; Yue C
J Gene Med; 2024 Jan; 26(1):e3600. PubMed ID: 37776237
[TBL] [Abstract][Full Text] [Related]
6. Hsa_circ_0001756 promotes ovarian cancer progression through regulating IGF2BP2-mediated RAB5A expression and the EGFR/MAPK signaling pathway.
Ji J; Li C; Wang J; Wang L; Huang H; Li Y; Fang J
Cell Cycle; 2022 Apr; 21(7):685-696. PubMed ID: 35113003
[TBL] [Abstract][Full Text] [Related]
7. [Knockdown of IGF2BP2 inhibits colorectal cancer cell proliferation, migration and promotes tumor immunity by down-regulating MYC expression].
Liu T; Han C; Hu C; Mao S; Sun Y; Yang S; Yang K
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Apr; 39(4):303-310. PubMed ID: 37087547
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
9. IGF2BP2 promotes ovarian cancer growth and metastasis by upregulating CKAP2L protein expression in an m
Shi Y; Xiong X; Sun Y; Geng Z; Chen X; Cui X; Lv J; Ge L; Jia X; Xu J
FASEB J; 2023 Oct; 37(10):e23183. PubMed ID: 37665628
[TBL] [Abstract][Full Text] [Related]
10. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
[TBL] [Abstract][Full Text] [Related]
11. ALKBH5 modulates macrophages polarization in tumor microenvironment of ovarian cancer.
An Y; Duan H
J Ovarian Res; 2024 Apr; 17(1):84. PubMed ID: 38637813
[TBL] [Abstract][Full Text] [Related]
12. Single-cell and transcriptomic analyses reveal the influence of diabetes on ovarian cancer.
Zhao Z; Wang Q; Zhao F; Ma J; Sui X; Choe HC; Chen P; Gao X; Zhang L
BMC Genomics; 2024 Jan; 25(1):1. PubMed ID: 38166541
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive bioinformatics analysis confirms RBMS3 as the central candidate biological target for ovarian cancer.
Wang M; Fu X; Wang W; Zhang Y; Jiang Z; Gu Y; Chu M; Shao Y; Li S
Med Eng Phys; 2022 Dec; 110():103883. PubMed ID: 36075788
[TBL] [Abstract][Full Text] [Related]
14. GNPNAT1 is a potential biomarker correlated with immune infiltration and immunotherapy outcome in breast cancer.
Yuan R; Zhang Y; Wang Y; Chen H; Zhang R; Hu Z; Chai C; Chen T
Front Immunol; 2023; 14():1152678. PubMed ID: 37215111
[TBL] [Abstract][Full Text] [Related]
15. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis.
Wang S; Li Z; Zhu G; Hong L; Hu C; Wang K; Cui K; Hao C
J Ovarian Res; 2021 Nov; 14(1):154. PubMed ID: 34774079
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of IGF2BP2 Promotes Oral Squamous Cell Carcinoma Progression That Is Related to Cell Proliferation, Metastasis and Tumor-Infiltrating Immune Cells.
Zhou L; Li H; Cai H; Liu W; Pan E; Yu D; He S
Front Oncol; 2022; 12():809589. PubMed ID: 35299748
[TBL] [Abstract][Full Text] [Related]
17. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
18. KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.
Zhu S; Bao H; Zhang MC; Liu H; Wang Y; Lin C; Zhao X; Liu SL
BMC Cancer; 2022 Jun; 22(1):662. PubMed ID: 35710397
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis.
Liu T; Shen J; He Q; Xu S
Front Genet; 2022; 13():814291. PubMed ID: 35237300
[TBL] [Abstract][Full Text] [Related]
20. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
